Vandria announces $20.6M Series A Financing led by ND Capital to drive CNS Clinical Program and Mitochondrial Therapeutics Platform
21 décembre 2023 – Vandria SA, a company at the vanguard of mitochondrial therapeutics developing first-in-class small molecule mitophagy inducers, emerged from stealth with the announcement of its successful Series A fundraise. The $20.6M round was led by ND Capital together with a small syndicate of HNW private investors.
Walder Wyss advised Vandria SA in this transaction. The team was led by Luc Defferrard (Partner, Corporate/M&A) and further included Michael Kündig (Senior Associate, Corporate/M&A) and Sébastien Aubert (Associate, Corporate M&A).